Johnson & Johnson announced the acquisition of TARIS Biomedical LLC (TARIS), a privately-owned biotechnology company specializing in the development of a novel drug delivery technology for the treatment of bladder diseases including cancer. The company’s lead clinical-stage product, TAR-200, uses the proprietary TARIS System, which features a silicone-based drug delivery device that allows for the

On January 2nd, the Psomagen-Macrogen Consortium announced the acquisition of all key assets of US company uBiome. Through the move, Psomagen has become a key player in the microbiome sector, a promising next-generation bio healthcare industry, with a competitive advantage in the US and global markets. The acquisition includes a microbiome patent portfolio comprising 246

DNA sequencer makers Illumina and Pacific Biosciences of California called off their $1.2 billion merger that’s been in the works for over a year after the Federal Trade Commission (FTC) challenged the transaction and described it as “monopolist.” “Considering the lengthy regulatory approval process the transaction has already been subject to and continued uncertainty of

Charles River Laboratories International, Inc. (NYSE: CRL) announced that it has completed the previously announced acquisition of HemaCare Corporation (OTCMKTS: HEMA) for approximately $380 million in cash, or $25.40 per HemaCare share. HemaCare will become part of Charles River’s Research Models and Services segment. HemaCare is a leader in the production of human-derived cellular products

Melinta Therapeutics, Inc. (NASDAQ: MLNT) (the “Company” or “Melinta”), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, announced that it has entered into a Restructuring Support Agreement (the “Agreement”) with the lenders under its senior credit facility, Deerfield Private Design Fund III, L.P. and Deerfield Private

Urovant Sciences (Nasdaq: UROV) (“Urovant”) announced that its majority shareholder, Roivant Sciences Ltd. (“Roivant”), and Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506) (“Sumitomo Dainippon Pharma”), a leading global Japanese pharmaceutical company, have completed their transaction that creates a significant, multinational Sumitomo Dainippon Pharma-Roivant Alliance (“Alliance”), including the transfer of Roivant’s ownership interests in Urovant, as